Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027GlobeNewsWire · 4 days ago
What Makes Acrivon Therapeutics, Inc. (ACRV) a New Buy StockZacks Investment Research · Sep 15, 2026
Acrivon Therapeutics, Inc. (ACRV) Just Flashed Golden Cross Signal: Do You Buy?Zacks Investment Research · Sep 3, 2026
Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare ConferenceGlobeNewsWire · Sep 2, 2026
Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business OfficerGlobeNewsWire · Aug 31, 2026
Here's Why Acrivon Therapeutics, Inc. (ACRV) is a Great Momentum Stock to BuyZacks Investment Research · Aug 24, 2026Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$0.50 | -$0.43 | Beat |
| May 13, 2026 | -$0.49 | -$0.49 | Beat |
| Mar 19, 2026 | -$0.49 | -$0.49 | Beat |
| Nov 13, 2025 | -$0.57 | -$0.47 | Beat |
| Aug 13, 2025 | -$0.57 | -$0.55 | Beat |
| May 14, 2025 | -$0.57 | -$0.51 | Beat |